Business Insider

Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)

First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies Topline safety, PK, and PD data anticipated in Q1 2026 Advances ongoing ...
Morningstar

Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn’s Disease (FSCD) | Morningstar

Data from this Phase 1b FSCD study, together with results from Palisade’s completed Phase 1a/1b trials in ulcerative colitis, will support the Company’s planned Phase 2 IND submission to the U.S. Food ...